Platinum-based chemotherapy has remained the standard of care for the treatment of platinum-sensitive ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and more recently PARP inhibitors, have entered the therapeutic landscape for this indication. Due to the regulatory approval of targeted therapies, such as Roche/Genentech’s Avastin, AstraZeneca’s Lynparza, Tesaro’s Zejula, and Clovis Oncology’s Rubraca, the market is more crowded leading to higher barriers of entry for emerging therapies in platinum-sensitive ovarian cancer. However, areas of unmet need for the treatment of platinum-sensitive ovarian cancer remain. This content evaluates the key drivers of prescribing and analyzes the areas of significant commercial opportunities that could be valuable commercial opportunities for developers.
- What are the treatment drivers and goals for platinum-sensitive ovarian cancer?
- What attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for platinum-sensitive ovarian cancer?
- What are the prevailing areas of unmet need and opportunity in platinum-sensitive ovarian cancer?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new therapy for platinum-sensitive ovarian cancer?
Markets covered: United States, United Kingdom, France, and Germany.
Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in April 2017.
Key companies: Roche/Genentech, AstraZeneca, Tesaro, Clovis Oncology.
Key drugs: Carboplatin/Paclitaxel, Avastin, Lynparza, Zejula, Rubraca.